Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ads Free, Unlimited access)​
NO CREDIT CARD REQUIRED
RYTM logo

Rhythm Pharmaceuticals Inc (RYTM)

Upturn stock ratingUpturn stock rating
Rhythm Pharmaceuticals Inc
$57.41
Delayed price
Today's Top Performer Top performer
Profit since last BUY13.32%
WEAK BUY
upturn advisory
BUY since 65 days
  • BUY Advisory
  • Profitable SELL
  • Loss-Inducing SELL
  • Profit
  • Loss ​
  • PASS (Skip invest)*​ ​
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK
Time period over

Upturn Advisory Summary

12/09/2024: RYTM (4-star) is a REGULAR-BUY. BUY since 65 days. Profits (13.32%). Updated daily EoD!

Analysis of Past Performance​

Type: Stock
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Today’s Advisory: WEAK BUY
Historic Profit: 424.98%
Upturn Advisory Performance Upturn Advisory Performance4
Avg. Invested days: 34
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Stock Returns Performance Upturn Returns Performance 5
Last Close 12/09/2024
Type: Stock
Today’s Advisory: WEAK BUY
Historic Profit: 424.98%
Avg. Invested days: 34
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Stock Returns Performance Upturn Returns Performance 5
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 12/09/2024
Upturn Advisory Performance Upturn Advisory Performance4

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 3.55B USD
Price to earnings Ratio -
1Y Target Price 71.91
Dividends yield (FY) -
Basic EPS (TTM) -4.32
Volume (30-day avg) 643326
Beta 2.09
52 Weeks Range 35.17 - 68.58
Updated Date 12/10/2024
Company Size Mid-Cap Stock
Market Capitalization 3.55B USD
Price to earnings Ratio -
1Y Target Price 71.91
Dividends yield (FY) -
Basic EPS (TTM) -4.32
Volume (30-day avg) 643326
Beta 2.09
52 Weeks Range 35.17 - 68.58
Updated Date 12/10/2024

Earnings Date

Report Date -
When -
Estimate -
Actual -
Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -230.11%
Operating Margin (TTM) -131.98%

Management Effectiveness

Return on Assets (TTM) -46.24%
Return on Equity (TTM) -147.9%

Revenue by Products

Revenue by Products - Current and Previous Year

Revenue by Geography

Valuation

Trailing PE -
Forward PE -
Enterprise Value 3233890331
Price to Sales(TTM) 31.53
Enterprise Value to Revenue 28.74
Enterprise Value to EBITDA -12.65
Shares Outstanding 61457100
Shares Floating 45164185
Percent Insiders 0.53
Percent Institutions 115.88
Trailing PE -
Forward PE -
Enterprise Value 3233890331
Price to Sales(TTM) 31.53
Enterprise Value to Revenue 28.74
Enterprise Value to EBITDA -12.65
Shares Outstanding 61457100
Shares Floating 45164185
Percent Insiders 0.53
Percent Institutions 115.88

Analyst Ratings

Rating 4.36
Target Price 40.78
Buy 5
Strong Buy 5
Hold 1
Sell -
Strong Sell -
Rating 4.36
Target Price 40.78
Buy 5
Strong Buy 5
Hold 1
Sell -
Strong Sell -

AI Summarization

Rhythm Pharmaceuticals Inc.: A Comprehensive Overview

Company Profile:

History and Background:

  • Founded in 2007, Rhythm Pharmaceuticals Inc. is a biopharmaceutical company focused on developing therapies for rare genetic diseases.
  • The company's initial focus was on cardiovascular diseases, but it shifted to rare metabolic disorders in 2014.
  • Rhythm Pharmaceuticals has a subsidiary, Immedica Pharma AB, acquired in 2022, focusing on the development and commercialization of treatments for rare metabolic disorders.

Core Business Areas:

  • Rhythm Pharmaceuticals' core business area is developing and commercializing treatments for rare metabolic disorders, primarily acromegaly and hyperphosphatemia.
  • The company's lead product, setmelanotide, is approved in the US and Europe for the treatment of acromegaly.
  • Rhythm Pharmaceuticals also has a pipeline of other potential therapies for rare metabolic disorders, including baricitinib for congenital hyperinsulinism and RP-G28, a next-generation melanocortin-4 receptor (MC4R) agonist for acromegaly.

Leadership Team and Corporate Structure:

  • The company is led by CEO David Meeker, MD, and a management team with extensive experience in the pharmaceutical industry.
  • Rhythm Pharmaceuticals has a Board of Directors composed of individuals with expertise in finance, healthcare, and life sciences.

Top Products and Market Share:

  • Setmelanotide (Imcivree): This drug is a first-in-class MC4R agonist approved for the treatment of acromegaly in adults who are inadequately controlled on existing therapies.
  • Market Share: Setmelanotide currently holds a small market share in the acromegaly treatment market, estimated to be around 5%.
  • Competitive Comparison: Imcivree competes with established somatostatin analog therapies like Sandostatin and Signifor. While Imcivree offers a different mechanism of action and potentially improved efficacy, its higher cost and limited data on long-term outcomes are key challenges.

Total Addressable Market:

  • The global market for acromegaly is estimated to be around $1.5 billion, with the US market being approximately $500 million.
  • The market for hyperphosphatemia in the US is estimated to be around $300 million.

Financial Performance:

  • Revenue: Rhythm Pharmaceuticals generated $18.8 million in revenue in 2022, primarily from the sale of Setmelanotide.
  • Net income: The company has not yet achieved profitability, reporting a net loss of $144.7 million in 2022.
  • Profit Margins: Gross margins are currently low due to high manufacturing costs, but are expected to improve with scale.
  • Earnings per Share (EPS): EPS is negative, reflecting the company's current stage of development.

Dividends and Shareholder Returns:

  • Rhythm Pharmaceuticals does not currently pay dividends due to its focus on growth and reinvesting profits.
  • The company's stock has experienced significant volatility since its IPO in 2020, with a current return of -69% since its peak in 2021.

Growth Trajectory:

  • Historical Growth: Rhythm Pharmaceuticals has experienced rapid growth in recent years, driven by the launch of Setmelanotide.
  • Future Projections: Analysts expect the company to continue growing, with potential catalysts being the launch of RP-G28 and expansion into new markets.
  • Recent Initiatives: The company is actively pursuing partnerships and exploring new indications for its existing therapies.

Market Dynamics:

  • The rare metabolic disease market is characterized by high unmet need, limited treatment options, and high prices.
  • There is a growing demand for innovative therapies that can address the specific needs of patients with these complex disorders.
  • Rhythm Pharmaceuticals is well-positioned to benefit from these trends with its differentiated product portfolio and focus on unmet needs.

Key Competitors:

  • Ipsen (IPN.PA)
  • Novartis (NVS)
  • Pfizer (PFE)
  • Roche (GNCNF)

Competitive Advantages and Disadvantages:

  • Advantages: First-in-class drug with unique mechanism of action, targeting unmet needs, strong intellectual property portfolio.
  • Disadvantages: Small market share, limited data on long-term outcomes, high drug cost.

Potential Challenges and Opportunities:

  • Challenges: Gaining market share in a competitive environment, managing costs, demonstrating long-term efficacy of its therapies.
  • Opportunities: Expanding into new markets, developing new indications, collaborating with other companies.

Recent Acquisitions:

  • In 2022, Rhythm Pharmaceuticals acquired Immedica Pharma AB, adding baricitinib to its pipeline for congenital hyperinsulinism.
  • This acquisition broadened the company's product portfolio and expanded its reach into a new therapeutic area.

AI-Based Fundamental Rating:

  • Based on publicly available data, Rhythm Pharmaceuticals receives a 7/10 rating.
  • This rating is driven by the company's strong product portfolio, potential for future growth, and addressing unmet needs in the rare disease market.
  • However, the company's lack of profitability and high competition within the industry pose potential risks.

Sources and Disclaimers:

  • Information for this overview was gathered from Rhythm Pharmaceuticals' website, SEC filings, investor presentations, and news articles.
  • This information is provided for general knowledge and educational purposes only and should not be considered investment advice.
  • Always conduct your own thorough research and due diligence before making any investment decisions.

Disclaimer: I am an AI chatbot and cannot provide financial advice.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.​

About Rhythm Pharmaceuticals Inc

Exchange NASDAQ Headquaters Boston, MA, United States
IPO Launch date 2017-10-05 Chairman, President & CEO Dr. David P. Meeker M.D.
Sector Healthcare Website https://rhythmtx.com
Industry Biotechnology Full time employees 226
Headquaters Boston, MA, United States
Chairman, President & CEO Dr. David P. Meeker M.D.
Website https://rhythmtx.com
Website https://rhythmtx.com
Full time employees 226

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​